EIF3B

Across TCGA pan-cancer cohorts, EIF3B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EIF3B data layer compared with 26 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher EIF3B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EIF3B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, OV, and UCEC are the cancer types where EIF3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.095	0.830	<.001	36	view →
OV	OS	Median	II,III,IV	0.304	0.691	.030	18	view →
UCEC	DFS	Median	All	1.000	0.621	.012	16	view →
SARC	OS	Median	All	0.127	0.860	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EIF3B–CESC (OS)

Open the CESC breakdown →